This suggests that avasimibe is targeting signaling pathways that are differentially activated in mutation-independent resistant CML compared to imatinib-naïve CML, or CML where resistance is a result of a BCR-ABL kinase-domain point mutation. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.